Tags

Type your tag names separated by a space and hit enter

Clinical-pathological prognostic factors and treatment failure patterns in T1-2 high-grade parotid gland cancer.
Oral Oncol. 2020 Jul 03; 110:104884.OO

Abstract

OBJECTIVES

The purpose of this study was to evaluate the treatment outcomes of patients with T1-2, high-grade parotid cancer, and to analyze the prognostic factors and treatment failure patterns.

MATERIALS AND METHODS

Of the 101 patients who were diagnosed with high-grade parotid cancer from March 2003 to December 2018, a total of 39 males and 23 females who had T1-2 tumor were enrolled in this study.

RESULTS

The average follow-up period of patients in this study was 63.9 months. The 5-year overall survival rate was 73.0%, and the 5-year disease-free survival rate was 57.6%. Thirty-nine patients underwent less-than-total parotidectomies, and the remaining 23 patients underwent total parotidectomies. After surgery, 50 patients received adjuvant treatment. During the study, 25 recurrences were documented, including nine local recurrences and 16 distant metastases. The average time period between the end of initial treatment and disease relapse was 17.0 months. A total of 16 patients succumbed to disease progression. Multivariate Cox proportional regression analysis showed that lymphovascular invasion (LVI) was an independent prognostic factor affecting disease recurrence and patient deaths. Among various factors, LVI and lymph node (LN) metastasis showed statistically significant correlations with distant metastasis.

CONCLUSION

Although we achieved favorable therapeutic results using standard treatments in selected patients, T1-2 high-grade parotid cancers generally have poor prognosis. Distant metastases that occur during follow-up are a major factor in treatment failure and LVI and LN metastasis are significantly associated with distant metastasis.

Authors+Show Affiliations

Department of Otorhinolaryngology, Yonsei University College of Medicine, Gangnam Severance Hospital, Seoul, Republic of Korea.Department of Pathology, Yonsei University College of Medicine, Seoul, Republic of Korea.Department of Otorhinolaryngology, Yonsei University College of Medicine, Seoul, Republic of Korea.Department of Otorhinolaryngology, Yonsei University College of Medicine, Seoul, Republic of Korea.Department of Otorhinolaryngology, Yonsei University College of Medicine, Gangnam Severance Hospital, Seoul, Republic of Korea. Electronic address: jylimmd@yuhs.ac.Department of Otorhinolaryngology, Yonsei University College of Medicine, Seoul, Republic of Korea. Electronic address: eunchangmd@yuhs.ac.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

32629407

Citation

Park, Young Min, et al. "Clinical-pathological Prognostic Factors and Treatment Failure Patterns in T1-2 High-grade Parotid Gland Cancer." Oral Oncology, vol. 110, 2020, p. 104884.
Park YM, Yoon SO, Koh YW, et al. Clinical-pathological prognostic factors and treatment failure patterns in T1-2 high-grade parotid gland cancer. Oral Oncol. 2020;110:104884.
Park, Y. M., Yoon, S. O., Koh, Y. W., Kim, S. H., Lim, J. Y., & Choi, E. C. (2020). Clinical-pathological prognostic factors and treatment failure patterns in T1-2 high-grade parotid gland cancer. Oral Oncology, 110, 104884. https://doi.org/10.1016/j.oraloncology.2020.104884
Park YM, et al. Clinical-pathological Prognostic Factors and Treatment Failure Patterns in T1-2 High-grade Parotid Gland Cancer. Oral Oncol. 2020 Jul 3;110:104884. PubMed PMID: 32629407.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Clinical-pathological prognostic factors and treatment failure patterns in T1-2 high-grade parotid gland cancer. AU - Park,Young Min, AU - Yoon,Sun Och, AU - Koh,Yoon Woo, AU - Kim,Se-Heon, AU - Lim,Jae-Yol, AU - Choi,Eun Chang, Y1 - 2020/07/03/ PY - 2020/03/20/received PY - 2020/06/29/revised PY - 2020/06/29/accepted PY - 2020/7/7/pubmed PY - 2020/7/7/medline PY - 2020/7/7/entrez KW - Distant metastasis KW - High-grade parotid gland cancer KW - Lymph node metastasis KW - Lymphovascular invasion SP - 104884 EP - 104884 JF - Oral oncology JO - Oral Oncol. VL - 110 N2 - OBJECTIVES: The purpose of this study was to evaluate the treatment outcomes of patients with T1-2, high-grade parotid cancer, and to analyze the prognostic factors and treatment failure patterns. MATERIALS AND METHODS: Of the 101 patients who were diagnosed with high-grade parotid cancer from March 2003 to December 2018, a total of 39 males and 23 females who had T1-2 tumor were enrolled in this study. RESULTS: The average follow-up period of patients in this study was 63.9 months. The 5-year overall survival rate was 73.0%, and the 5-year disease-free survival rate was 57.6%. Thirty-nine patients underwent less-than-total parotidectomies, and the remaining 23 patients underwent total parotidectomies. After surgery, 50 patients received adjuvant treatment. During the study, 25 recurrences were documented, including nine local recurrences and 16 distant metastases. The average time period between the end of initial treatment and disease relapse was 17.0 months. A total of 16 patients succumbed to disease progression. Multivariate Cox proportional regression analysis showed that lymphovascular invasion (LVI) was an independent prognostic factor affecting disease recurrence and patient deaths. Among various factors, LVI and lymph node (LN) metastasis showed statistically significant correlations with distant metastasis. CONCLUSION: Although we achieved favorable therapeutic results using standard treatments in selected patients, T1-2 high-grade parotid cancers generally have poor prognosis. Distant metastases that occur during follow-up are a major factor in treatment failure and LVI and LN metastasis are significantly associated with distant metastasis. SN - 1879-0593 UR - https://www.unboundmedicine.com/medline/citation/32629407/Clinical-pathological_prognostic_factors_and_treatment_failure_patterns_in_T1-2_high-grade_parotid_gland_cancer L2 - https://linkinghub.elsevier.com/retrieve/pii/S1368-8375(20)30320-1 DB - PRIME DP - Unbound Medicine ER -
Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.